ATG16L1 and colorectal carcinoma: Our current study indicates that high ATG16L1 expression predicts poor immunotherapy response in CRC, which can be explained mechanistically by ATG16L1-mediated inhibition of IFN signaling and a consequent suppression of cellular immunity.